This study evaluated humoral immune memory following mRNA-based COVID-19 booster vaccination in people with inflammatory bowel disease (IBD) receiving intravenous anti-TNF therapy compared with control participants. The cohort comprised 27 IBD patients on anti-TNF treatment and 44 controls. Blood samples were collected at baseline, 1 month and 6 months after booster vaccination to assess both serum antibody responses and antigen-specific memory B cells (Bmem).
Participants received either an ancestral WH1/BA.5 bivalent mRNA booster or an XBB.1.5 monovalent mRNA booster. Laboratory measures included infectious virus neutralization assays for functional neutralizing antibodies, ELISA quantification of serum SARS-CoV-2 spike receptor binding domain (RBD)-specific IgG, and flow cytometric immunophenotyping of RBD-specific Bmem. Recombinant RBD proteins from the ancestral strain and Omicron subvariants (BA.1, BA.5, XBB.1.5 and JN.1) were used to define variant-specific Bmem binding.
In patients receiving anti-TNF therapy, serum RBD-specific IgG and neutralizing antibody titers increased from pre-vaccination baseline to 1 month after booster vaccination, demonstrating that boosting elicits a measurable humoral response in this group. However, absolute antibody levels and neutralizing activity in anti-TNF-treated patients were lower than those observed in control participants at the corresponding timepoints. The authors report reduced magnitude and apparent durability of antibody responses in the anti-TNF group compared with controls.
Vaccination increased the frequency of RBD-specific Bmem recognizing the ancestral RBD as well as Omicron-derived BA.5 and XBB.1.5 RBDs in both study groups. Despite this post-vaccination rise, frequencies of antigen-specific Bmem were significantly lower in anti-TNF-treated patients than in controls. When probing binding to multiple variant RBDs, more RBD-specific Bmem overall recognized multiple viral variants after vaccination, but the number of Bmem capable of binding Omicron subvariants was reduced in the anti-TNF group relative to controls.
Within the RBD-specific Bmem compartment, the study assessed activation and isotype markers. Frequencies of recently activated CD21lo RBD-specific Bmem increased after vaccination in both cohorts; importantly, the proportion of CD21lo cells among antigen-specific Bmem was higher in anti-TNF-treated patients than in controls, indicating a skewed activation phenotype in the context of anti-TNF therapy.
Isotype analysis demonstrated differences between groups after vaccination: fewer antigen-specific Bmem in anti-TNF-treated patients expressed IgG4, whereas a larger fraction expressed IgG3 or retained IgD. These shifts in isotype distribution may reflect altered class-switching or maturation of antigen-specific B cells associated with anti-TNF therapy.
Although booster vaccination broadened the variant recognition profile of RBD-specific Bmem across the cohort, anti-TNF-treated patients had a reduced capacity for cross-recognition of Omicron subvariants. The combined findings for lower antibody titers, reduced Bmem frequencies, altered activation phenotype, and diminished cross-reactivity suggest a reduced capacity and potential decreased durability of immune memory against breakthrough infection in this patient population.
The authors conclude that IBD patients receiving intravenous anti-TNF therapy exhibit impaired antibody and memory B-cell responses to mRNA COVID-19 booster vaccination compared with controls. Specifically, responses showed reduced magnitude, altered Bmem phenotype and lower cross-reactivity to Omicron subvariants. The preprint interprets these results as evidence of impaired immune memory that may increase susceptibility to breakthrough infection and supports recommendations for annual booster vaccination to reduce risk of severe disease and viral spread. As this report is a preprint, the results have not been peer reviewed; the manuscript also notes that all generated data are contained within the paper.
The study authors report ethical approvals from the Alfred Health ethics committee (32/21), Monash University (72794) and Erasmus University Medical Center (MEC-2022-0462) and state that participant consent procedures were followed. Competing interests disclosed include inventors on a related patent application for MCvZ, REOH and PMH; all other authors declared no conflicts. Funding was provided by the Australian Medical Research Future Fund (2016108). The manuscript is a medRxiv preprint and has not been certified by peer review.